CKD-MBD can lead to bone fragility, either with high bone turnover or low bone turnover.

Adynamic bone disease is characterized by a low-bone-turnover state.

Bone biopsy remains the diagnostic gold standard for adynamic bone disease.

Aggressive PTH suppression can increase the risk of this disease process.

Novel, anabolic agents may play a therapeutic role in ABD management.